A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is a multicenter, open-label, observational, postmarketing surveillance study of Genentech growth hormone (GH) products in the treatment of girls with Turner syndrome in the United States and Canada.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
up to 17 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Primary care clinic
Are girls with Turner syndrome who are being or will be treated with Nutropin, Nutropin AQ, or Protropin
Are willing to keep follow-up appointments throughout study participation
Are girls with Turner syndrome who have submitted Form 4 upon discontinuation and may also submit Form 9
Have Noonan syndrome
Subjects treated within the last 6 months with a non-Genentech GH preparation
Primary Ovarian Insufficiency
Disorders of Sex Development
Sex Chromosome Disorders of Sex Development
Heart Defects, Congenital
Sex Chromosome Disorders
Genetic Diseases, Inborn
Endocrine System Diseases
Genital Diseases, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs